The Women’s Tennis Association (WTA) has introduced a new requirement that all competitors on the women’s circuit must undergo a genetic test to confirm their biological sex before they are allowed to participate in official events. This policy update, which will be enforced beginning on Tuesday, mandates a one‑time screening for the presence of the SRY gene – the genetic marker that determines male biological characteristics.
Players who decline to submit to the test will face disciplinary measures, potentially including suspension or exclusion from tournaments. Under the previous set of rules, the WTA permitted transgender women to compete provided they publicly identified as female and kept their testosterone levels below a specified threshold for a continuous period of two years. Those guidelines were intended to balance inclusion with competitive fairness. However, the association has now shifted to a more definitive biological criterion, citing the need for a clear, objective standard that can be uniformly applied across all levels of the sport.
At present, there are no known transgender women competing on the WTA Tour, nor are there any documented cases at the lower tiers of professional tennis. The new testing protocol therefore primarily serves as a preventative measure, aiming to pre‑empt any future disputes over eligibility and to align tennis with policies already adopted by other international sporting bodies.
In a formal press release, the WTA explained that the updated eligibility framework is designed to "provide a clear eligibility standard for participation in WTA tournaments." The statement emphasized that the screening will be conducted only once for each athlete, with the results securely stored and handled in accordance with strict confidentiality and data‑privacy regulations. The organization also highlighted that the rollout of the testing program will be accompanied by a comprehensive player‑engagement initiative, ensuring that athletes are fully informed about the process, their rights, and the safeguards in place to protect their personal information. The testing schedule is slated to commence in 2026. During that year, the WTA will work closely with medical professionals, genetic laboratories, and legal advisors to guarantee that the procedure is both scientifically sound and ethically responsible.
Players will receive detailed guidance on how the sample will be collected, how the data will be used, and what steps will be taken should any disputes arise. The WTA acknowledged that the issue of sex verification is "sensitive and complex," and pledged to treat every athlete with dignity and respect throughout the implementation of the new rule. The association underscored its commitment to a respectful, thoughtful approach that recognizes the personal nature of gender identity while also safeguarding the integrity of competition.
This move follows similar actions taken by other global sport federations. In 2025, World Athletics and the International Boxing Association (IBA) instituted mandatory SRY testing for female athletes competing at elite levels. Those organizations reported that the genetic screening helped to clarify eligibility questions and reduce controversy, though they also faced criticism from advocacy groups concerned about privacy and the potential for discrimination.
The WTA’s decision has sparked a range of reactions within the tennis community. Some former players and commentators argue that the genetic test is a necessary tool to ensure a level playing field, especially as the sport continues to evolve and attract a broader, more diverse pool of talent. Others, including several human‑rights organizations, have expressed concern that reliance on a single genetic marker may overlook the nuanced spectrum of biological sex and gender identity, and they caution against policies that could marginalize athletes who do not fit neatly into binary categories.
From a practical standpoint, the introduction of mandatory SRY testing will require logistical coordination across tournaments worldwide. Each event will need to allocate resources for sample collection, secure transport to accredited laboratories, and verification of results before the start of competition.
The WTA has indicated that it will fund these processes and work with national tennis federations to ensure consistent application of the rule. In addition to the testing protocol, the WTA plans to launch an educational campaign aimed at players, coaches, and fans. This campaign will cover topics such as the science behind the SRY gene, the legal framework supporting the policy, and the steps athletes can take if they have concerns about their privacy or the testing outcome. By providing transparent information, the association hopes to mitigate misunderstandings and foster a climate of acceptance.
Looking ahead, the WTA’s policy could set a precedent for other sports that have yet to adopt genetic verification methods. As more governing bodies grapple with the balance between inclusivity and fairness, the outcomes of the WTA’s implementation—both in terms of competitive integrity and athlete welfare—will likely be closely monitored.
Critics will watch for any unintended consequences, such as potential legal challenges or negative impacts on the mental health of players subjected to the testing process. Overall, the WTA’s mandatory SRY gene screening represents a significant shift in how the sport addresses questions of gender eligibility. By instituting a clear, science‑based standard, the organization aims to protect the fairness of competition while also pledging to handle the process with the utmost respect for the individuals involved.
The coming months will reveal how effectively the policy can be integrated into the existing tournament structure and whether it will achieve the intended balance between competitive equity and the respectful treatment of all athletes.